AIM Biotech is leading the shift from preclinical animal models to humanized in vitro physiological models for the discovery of new medicines.
Researchers and regulators around the globe know that when it comes to predicting drug efficacy, animal models too often lead us down the wrong path. That is why they are demanding non-animal, in vitro models for drug discovery research.
AIM Biotech is answering the call with our idenTx and organiX humanized 3D microfluidic platforms. These systems combine unmatched recapitulation of human biology with unparalleled ease-of-use, resulting in a powerful solution to move medicine forward.
From our simple-to-use microfluidic platforms to our full service contract research offerings for Cancer, Immuno-oncology, Vascular Biology and Neurobiology, AIM Biotech is leading the non-animal drug discovery revolution.